[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-563446-105":3,"detail-sidebar-cat-1-en-105":81,"doc-detail-563446-en":127},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","zepbound-tirzepatide-injection-prescribing-information-highlights","ZEPBOUND (tirzepatide) Injection - prescribing information highlights","","Highlights of ZEPBOUND (tirzepatide) injection provide key safety and effectiveness guidance for chronic weight management in adults. The document includes boxed warnings about thyroid C-cell tumor risk shown in rats and contraindications in patients with personal or family history of medullary thyroid carcinoma or MEN 2, plus counseling on symptoms. It outlines indications, limitations of use, weekly subcutaneous dosing starting at 2.5 mg, and maintenance options up to 15 mg, as well as major contraindications, warnings for gastrointestinal disease, kidney injury, gallbladder issues, pancreatitis, hypersensitivity, hypoglycemia risk, retinopathy complications, adverse reactions, drug interaction considerations, and use in specific populations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/general/","General",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/zepbound-tirzepatide-injection-prescribing-information-highlights/563446/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/zepbound-tirzepatide-injection-prescribing-information-highlights/563446.png","ImageObject",442,249,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-10-12",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is ZEPBOUND indicated for?","Question",{"text":63,"@type":64},"ZEPBOUND is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) plus at least one weight-related comorbidity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the boxed warning for ZEPBOUND?",{"text":68,"@type":64},"In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether ZEPBOUND causes thyroid C-cell tumors in humans, and patients with a personal or family history of MTC or MEN 2 are contraindicated.",{"name":70,"@type":61,"acceptedAnswer":71},"How is ZEPBOUND dosed and increased?",{"text":72,"@type":64},"The recommended starting dose is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase to 5 mg once weekly, then increase in 2.5 mg increments after at least 4 weeks on the current dose, with maintenance doses of 5 mg, 10 mg, or 15 mg once weekly.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},563446,1792086984,{"code":4,"msg":82,"data":83},"success",[84,89,94,99,104,109,114,119,124],{"id":85,"doc_module":22,"doc_module_name":25,"category_name":86,"show_sort_weight":87,"slug":88},11,"Presentations",90,"presentations",{"id":90,"doc_module":22,"doc_module_name":25,"category_name":91,"show_sort_weight":92,"slug":93},12,"Resumes",80,"resumes",{"id":95,"doc_module":22,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},14,"Invoices",70,"invoices",{"id":100,"doc_module":22,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},15,"Posters",60,"posters",{"id":105,"doc_module":22,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},16,"Social Media",50,"social-media",{"id":110,"doc_module":22,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},17,"Forms",40,"forms",{"id":115,"doc_module":22,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},18,"Letters",30,"letters",{"id":120,"doc_module":22,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},21,"Paper Templates",5,"papers-templates",{"id":125,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":4,"slug":126},158,"general-158",{"code":4,"msg":82,"data":128},{"doc_id":79,"user_id":129,"nickname":42,"user_avatar":130,"doc_module":22,"category_id":125,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":136,"language":137,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":138,"faqs":139,"seo_title":140,"seo_description":12,"update_tm":141,"read_time":95},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","1  \nHIGHLIGHTS OF PRESCRIBING INFORMATION  \nThese highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.  \nZEPBOUND® (tirzepatide) Injection, for subcutaneous use  \nInitial U.S. Approval: 2022  \nWARNING: RISK OF THYROID C-CELL TUMORS  \nSee full prescribing information for complete boxed warning.  \n• In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1) .  \n• ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) . Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (4, 5.1) .  \n----------------------------INDICATIONS AND USAGE---------------------------  \nZEPBOUND® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:  \n• 30 kg/m2 or greater (obesity) or  \n• 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. , hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease) . (1)  \nLimitations of Use:  \n• Coadministration with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended. (1)  \n• The safety and efficacy of coadministration with other products for weight management have not been established. ( 1)  \n• ZEPBOUND has not been studied in patients with a history of pancreatitis. (1)  \n------------------------DOSAGE AND ADMINISTRATION-----------------------  \n• The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. (2 .2)  \n• After 4 weeks, increase to 5 mg injected subcutaneously once weekly. (2 .2)  \n• Increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. (2 .2)  \n• The recommended maintenance dosages are 5 mg, 10 mg, or  \n15 mg injected subcutaneously once weekly. (2 .2)  \n• Consider treatment response and tolerability when selecting the maintenance dosage. (2 .2)  \n• The maximum dosage is 15 mg subcutaneously once weekly. (2 .2)  \n• Administer once weekly at any time of day, with or without meals.(2 .4)  \n• Inject subcutaneously in the abdomen, thigh, or upper arm. (2 .4)  \n• Rotate injection sites with each dose. (2 .4)  \n----------------------DOSAGE FORMS AND STRENGTHS---------------------  \nInjection: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial (3)  \n-------------------------------CONTRAINDICATIONS------------------------------  \n• Personal or family history of medullary thyroid carcinoma or inpatients with Multiple Endocrine Neoplasia syndrome type 2 (4)  \n• Known serious hypersensitivity to tirzepatide or any of the  \nexcipients in ZEPBOUND (4)  \n------------------------WARNINGS AND PRECAUTIONS-----------------------  \n• Severe Gastrointestinal Disease: Use has been associated with gastrointestinal adverse reactions, sometimes severe. Has not been studied in patients with severe gastrointestinal disease and isnot recommended in these patients. (5 .2)  \n• Acute Kidney Injury: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion. (5 .3)  \n• Acute Gallbladder Disease: Has been reported in clinical trials. If cholecystitis is suspected, gallbladder studies and clinical follow-up are indicated. (5 .4)  \n• Acute Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed. (5.5)  \n• Hypersensitivity Reaction","cbCaisI4578wLb8n","https://ap.wps.com/l/cbCaisI4578wLb8n","pdf",3878751,39,"English","# Highlights of Prescribing Information\n## Indications and Usage\n## Limitations of Use\n## Dosage and Administration\n## Dosage Forms and Strengths\n## Contraindications\n## Warnings and Precautions\n## Adverse Reactions\n## Drug Interactions\n## Use in Specific Populations","[{\"question\":\"What is ZEPBOUND indicated for?\",\"answer\":\"ZEPBOUND is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) plus at least one weight-related comorbidity.\"},{\"question\":\"What is the boxed warning for ZEPBOUND?\",\"answer\":\"In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether ZEPBOUND causes thyroid C-cell tumors in humans, and patients with a personal or family history of MTC or MEN 2 are contraindicated.\"},{\"question\":\"How is ZEPBOUND dosed and increased?\",\"answer\":\"The recommended starting dose is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase to 5 mg once weekly, then increase in 2.5 mg increments after at least 4 weeks on the current dose, with maintenance doses of 5 mg, 10 mg, or 15 mg once weekly.\"}]","ZEPBOUND (tirzepatide) Injection - prescribing information highlights | PDF",1791835500]